Glenmark Pharmaceuticals trades higher on getting EIR with VAI status for Goa facility
Glenmark Pharmaceuticals is currently trading at Rs. 2475.00, up by 12.00 points or 0.49% from its previous closing of Rs. 2463.00 on the BSE.
The scrip opened at Rs. 2465.00 and has touched a high and low of Rs. 2478.00 and Rs. 2457.25 respectively. So far 2708 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2536.85 on 28-Aug-2026 and a 52 week low of Rs. 1794.00 on 28-Oct-2025.
Last one week high and low of the scrip stood at Rs. 2,479.20 and Rs. 2,380.00 respectively. The current market cap of the company is Rs. 69526.05 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.53% and 13.81% respectively.
Glenmark Pharmaceuticals has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status. The inspection was conducted at the Company’s manufacturing facility from June 22, 2026 to June 30, 2026.
